Abstract
The geographic spread of persons infected with the 2019 novel coronavirus (2019-nCoV) provides an opportunity to study the natural history of the newly emerged virus. Migration events put travelers at risk of infection for the duration of their exposure to an area where transmission is known to occur. Using publicly available data of the ongoing epidemic of 2019-nCoV where event dates for cases have been shared, the present study estimated the incubation period and other time intervals that govern interpretation of the epidemiological dynamics of 2019-nCoV infections. Our results show that the incubation periods falls within the range of two to nine days with 95% confidence, and the median incubation period is 4–5 days when approximated using the Weibull distribution, which was the best fit model. The median time from illness onset to hospitalization was estimated at 3 days. Based on the estimate of the 95th percentile estimate of the incubation period, we recommend that the length of isolation and quarantine should be at least nine days. We also note that the median time delay of 13.8 days from illness onset to death should be considered when estimating the case fatality risk of this novel virus.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
H.N. received funding from the Japan Agency for Medical Research and Development (AMED) [grant number: JP18fk0108050]; the Japan Society for the Promotion of Science (JSPS) KAKENHI [grant numbers, H.N.: 17H04701, 17H05808, 18H04895 and 19H01074; R.K.: 18J21587], the Inamori Foundation, and the Japan Science and Technology Agency (JST) CREST program [grant number: JPMJCR1413]. SMJ and NML receive graduate study scholarships from the Ministry of Education, Culture, Sports, Science and Technology, Japan. B.Y. wishes to thank China Scholarship Council.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Used dataset is available as the Supplementary Material
